Celontin (Methsuximide) - Summary

CELONTIN SUMMARY

Celontin_®
(Methsuximide Capsules, USP)

Celontin (methsuximide) is an anticonvulsant succinimide, chemically designated as N,2-Dimethyl-2-phenylsuccinimide.

Celontin is indicated for the control of absence (petit mal) seizures that are refractory to other drugs.

CELONTIN NEWS HIGHLIGHTS

Media Articles Related to Celontin (Methsuximide)

Keppra XR Approved for Partial-Onset Seizures
Source: MedicineNet Seizure Specialty [2008.09.16]

Keppra XR(TM) Approved In The U.S. As Add-On To Other Antiepileptic Treatments For People With Partial Onset Seizures
Source: Epilepsy News From Medical News Today [2008.09.15]

Vimpat(R) Approved In Europe - First New Epilepsy Treatment For Partial-Onset Seizures In Three Years
Source: Epilepsy News From Medical News Today [2008.09.03]

FDA Approves First Generic Divalproex Sodium To Treat Seizures, Migraine Headaches And Bipolar Disorder
Source: Bipolar News From Medical News Today [2008.08.01]

Febrile Seizures
Source: MedicineNet Encephalitis and Meningitis Specialty [2008.05.09]

more>>

Published Studies Related to Celontin (Methsuximide)

Effective and safe but forgotten: methsuximide in intractable epilepsies in childhood. [2001.03]

Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction. [2000.05]

Serum protein binding of desmethyl-methsuximide. [1999.07]

Methsuximide therapy of juvenile myoclonic epilepsy. [1996.03]

Methsuximide for intractable childhood seizures. [1991.02]

more>>